Dermatomyositis Drug Market
- 2026 年市場規模
- USD 912 Mn
- 2033 年預估規模
- USD 1,216.3 Mn
- 年複合成長率 CAGR
- 4.2%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Dermatomyositis Drug Market, By Drug Type (Corticosteroids, Immunosuppressive Agents, Others), By Route of Administration (Oral, Topical, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Dermatomyositis (DM) is a rare inflammatory muscle disease that affects both the muscles as well as the skin. Dermatomyositis can strike people of all races, genders, and ages. Although, both males and females are affected equally in childhood, it is more common in females in adults. The exact cause of DM is unknown but it is believed to result from an immune-mediated process triggered by outside factors (e.g. malignancy, drugs, and infectious Drug Types) in genetically predisposed individuals. Dermatomyositis can occur with other connective tissue disorders such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren’s syndrome, and mixed connective tissue disease.
Market Dynamics
Key players operating in the global dermatomyositis drug market are focusing on adoption of growth strategies such as product approvals which is expected to drive the market growth during the forecast period. For instance, in July 2018, Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced that the U.S. Food and Drug Administration had granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Moreover, increasing research and development activities by key players for the treatment of dermatomyositis which is expected to drive the market growth over the forecast period. For instance, on October 21, 2019, CSL Behring,a biopharmaceutical company initiated phase 3 Study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in adults with dermatomyositis (DM). The study is estimated to be completed in February 2024.
Key features of the study
• This report provides an in-depth analysis of the global dermatomyositis drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dermatomyositis drug market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, Asahi Kasei Corporation., Octapharma USA, Healthcare Pharmaceuticals Limited., Zydus Cadila, Alkem Laboratories Ltd, Apotex Inc, Eli Lilly and Co, and F.Hoffman-La Roche Ltd
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global dermatomyositis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis drug market
Market Segmentation
• By Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
o Corticosteroids
o Immunosuppressive Agents
o Others
• By Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
o Oral
o Topical
o Others
• By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• By Region Insights (Revenue, USD Mn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East & Africa
GCC Countries
Israel
Rest of Middle East & Africa
• Key Players
o Pfizer Inc.
o Teva Pharmaceuticals USA, Inc.
o Hikma Pharmaceuticals PLC
o Asahi Kasei Corporation.
o Octapharma USA
o Healthcare Pharmaceuticals Limited.
o Zydus Cadila
o Alkem Laboratories Ltd
o Apotex Inc.
o Eli Lilly and Co
o Hoffman-La Roche Ltd
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Opportunity
o Impact Analysis
o Regulatory Scenario
o Market Trends
o Key Developments
o Epidemiology
o PEST Analysis
o Collaboration and Acquisition
o Porters Analysis
o Pipeline Analysis
4. Global Dermatomyositis Drug Market, By Drug Type, 2021-2033, (US$ Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Corticosteroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
o Immunosuppressive Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
5. Global Dermatomyositis Drug Market, By Route of Administration, 2021-2033, (US$ Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
o Topical
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Dermatomyositis Drug Market, By Distribution Channel, 2021-2033, (US$ Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
o Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
o Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
7. Global Dermatomyositis Drug Market, By Region, 2021-2033, (US$ Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021-2033, (US$ Mn)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Pfizer Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Teva Pharmaceuticals USA, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Hikma Pharmaceuticals PLC
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Asahi Kasei Corporation.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Octapharma USA
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Healthcare Pharmaceuticals Limited.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Zydus Cadila
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Alkem Laboratories Ltd
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Apotex Inc
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Eli Lilly and Co
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
F. Hoffman-La Roche Ltd
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
9. Section
o Research Methodology
o About us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們